Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 3/20 | 0.72 |
| ▸ | CPA3 | P15088 | 3/20 | 0.72 |
| ▸ | CPB1 | P15086 | 1/20 | 0.72 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.72 |
| ▸ | LTA4H | P09960 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393002 | 0.84 | CPA1 (1.00) | CPA1CPA3CPB1CPB2LTA4H | |
| SCHEMBL1915564 | 0.84 | CPA1 (1.00) | CPA1CPA3CPB1CPB2LTA4H | |
| SCHEMBL5688996 | 0.84 | CPA1 (1.00) | CPA1CPA3CPB1CPB2LTA4H | |
| SCHEMBL3421012 | 0.82 | CPA1 (0.96) | CPA1CPA3CPB1CPB2LTA4H | |
| SCHEMBL11248580 | 0.81 | CPA3 (0.72) | CPA1CPA3CPB1CPB2LTA4H | |
| SCHEMBL27663350 | 0.81 | CPA1 (0.72) | CPA1CPA3CPB1CPB2LTA4H | |
| SCHEMBL7540835 | 0.81 | CPA1 (0.72) | CPA1CPA3CPB1CPB2LTA4H | |
| SCHEMBL638640 | 0.79 | CPA1 (0.70) | CPA1CPA3CPB1CPB2LTA4H | |
| Succinic Acid SCHEMBL28290802 | 0.79 | CPA1 (0.89) | CPA1CPA3CPB1CPB2LTA4H | |
| SCHEMBL3842528 | 0.79 | CPA1 (0.64) | CPA1CPA3CPB1CPB2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785468-B2 | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | AMGEN INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | IAPP, INSR, AMY2A | CPA1 696/4885CPA3 2189/4885CPB1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.